The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Abstract
OBJECTIVE: To determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) is associated with increased risk of thyroid cancer. RESEARCH DESIGN AND METHODS: A nested case-control analysis was performed with use of the French national health care insurance system (SNDS) database. Individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006 and 2018 were included in the cohort. All thyroid cancers were identified through hospital discharge diagnoses and medical procedures between 2014 and 2018. Exposure to GLP-1 RA was measured within the 6 years preceding a 6-month lag-time period and considered as current use and cumulative duration of use based on defined daily dose (≤1, 1 to 3, >3 years). Case subjects were matched with up to 20 control subjects on age, sex, and length of diabetes with the risk-set sampling procedure. Risk of thyroid cancer related to use of GLP-1 RA was estimated with a conditional logistic regression with adjustment for goiter, hypothyroidism, hyperthyroidism, other antidiabetes drugs, and social deprivation index. RESULTS: A total of 2,562 case subjects with thyroid cancers were included in the study and matched with 45,184 control subjects. Use of GLP-1 RA for 1-3 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.27-1.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04-3.05). CONCLUSIONS: In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1-3 years of treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Concerns regarding the validity of outcomes have emerged, particularly owing to the reliance on indirect indicators such as the calcitonin test, carcinoembryonic antigen measurement, or vandetanib treatment to distinguish between MTC and non-MTC. This approach introduces the potential for misclassification.21,25”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“GLP-1 RA use for 1–3 years was associated with increased risk for any thyroid cancer (adjusted HR = 1.58 [CI 1.27–1.95]) and MTC (adjusted HR = 1.78 [CI 1.04–3.05]).25”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“In addition, five studies included analyses considering different lag times for outcome assessment, while two studies provided distinct information differentiating between thyroid cancer in general and MTC.25,38,51–53”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“GLP-1 RA use for 1–3 years was associated with increased risk for any thyroid cancer (adjusted HR = 1.58 [CI 1.27–1.95]) and MTC (adjusted HR = 1.78 [CI 1.04–3.05]).25”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Of note, there was a large variation in the percentage of cases reported as MTC between the two studies that included this distinction.25,38”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Two studies reported statistically significant findings of increased risk for thyroid cancer in those exposed to GLP-1 RA.25,38”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Of all thyroid cancer cases identified, 15% were MTC, which is higher than expected and might be related to methods used for defining MTC (e.g., testing for calcitonin test/carcinoembryonic antigen or vandetanib treatment).25”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Similarly, the potential for residual confounding (e.g., limited evaluation of specific risk factors for thyroid cancer such as obesity, neck radiation, and family history of thyroid cancer) and the role of surveillance bias (e.g., clinicians might be more likely to do a thyroid exam or ultrasound on patients taking GLP-1 RA) are important considerations that have been not thoroughly assessed.25,”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Consistent with previous studies, they also found a signal of disproportionate reporting of GLP-1 RA and overall thyroid cancer and MTC, including 606 reports (mostly from exenatide and liraglutide).25”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [25]
In the citing paper
“Recent investigations have highlighted the association between various neoplasms, such as thyroid, breast, and cholangiocarcinoma, and GLP-1 RAs [105-107].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [107]
In the citing paper
“the use of GLP-1 RAs for a duration of 1–3 years was associated with a heightened risk of all thyroid cancers, presenting an adjusted hazard ratio of 1.58 (95% CI 1.27–1.95) and an adjusted HR of 1.78 (95% CI 1.04–3.05), specifically for medullary thyroid cancer.”
In the citing paper
“A case-control study of health insurance data from France indicated an increased risk for thyroid carcinoma with GLP-1RA treatment, with an HR of 1.58 (95% CI 1.27–1.95) (78).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [78]
In the citing paper
“Recent health insurance data from France are indicative of an elevated risk of medullary thyroid carcinoma in individuals treated with GLP-1RAs versus other glucose-lowering agents (35 cases, hazard ratio [HR] 1.78 [95% CI 1.04–3.05]) (78).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [78]
In the citing paper
“in epidemiological studies a significant association with GLP-1RA treatment could be detected for medullary, but not for papillary cancer.12”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [12]
In the citing paper
“A similar problem affects observational studies; the main survey attempting to discriminate MTC from PTC 12 used indirect markers of limited reliability.21,22”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [12]
In the citing paper
“which was also confirmed by analyses of serious adverse events reported to the US Food and Drug Administration (FDA) 11,13 and the World Health Organization's pharmacovigilance database Vigi-Base.12,14”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [12]
In the citing paper
“Some retrospective observational studies detected an increased risk of thyroid cancer in association with GLP-1RA treatment, 11,12”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [12]
In the citing paper
“This meta-analysis suggests that GLP-1RA treatment may be associated with a moderate increase in risk of thyroid cancer, not dissimilar in its extent from that reported by a recent observational study, 12”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [12]
In the citing paper
“Also, the use of DPP4-i was found to be associated with a higher risk of thyroid cancer, leading the authors to hypothesize that this association might be partly explained by increased endogenous GLP-1 levels after the inhibition of DPP-4 [132].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [132]
In the citing paper
“The results showed that using GLP-1 RAs increased the risk of both medullary thyroid cancer and thyroid cancer overall, in particular after 1–3 years of treatment exposure (especially for male subjects) [132].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [132]
In the citing paper
“Also, the use of DPP4-i was found to be associated with a higher risk of thyroid cancer, leading the authors to hypothesize that this association might be partly explained by increased endogenous GLP-1 levels after the inhibition of DPP-4 [132].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [132]
Citations
Cites
van Puijenbroek, E., Bate, A., Leufkens, H. G. M., Lindquist, M., Orre, R., & Egberts, T. C. G. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.668 · Cited by 1,385
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Bezin, J., Duong, M., Lassalle, R., Droz‐Perroteau, C., Pariente, A., Blin, P., & Moore, N. D. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4233 · Cited by 586
Self-citationBiological actions and therapeutic potential of the glucagon-like peptides
Drucker, D. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.31068 · Cited by 509
Essebag, V., Platt, R. W., Abrahamowicz, M., & Pilote, L. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-5 · Cited by 234
Alves, C., Batel-Marques, F., & Macedo, A. F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.008 · Cited by 186
Asymptotic Theory for Nested Case-Control Sampling in the Cox Regression Model
Goldstein, L. J., & Langholz, B. M. (1992) · The Annals of Statistics · doi:10.1214/aos/1176348895 · Cited by 139
Nauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1825 · Cited by 94
Waser, B., Beetschen, K., Pellegata, N. S., & Reubi, J. C. (2011) · Neuroendocrinology · doi:10.1159/000330447 · Cited by 80
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 321
Ingram, Y., Olujide, O. P., Sheikh, N., Robinson, A., Ho, J. H., Syed, A. A., & Adam, S. (2025) · Current Oncology · doi:10.3390/curroncol32060362 · Cited by 13
The multifaceted effects of semaglutide: exploring its broad therapeutic applications
Alkhatib, M., Almasri, N., Alshwayyat, S., Almahariq, H., Hammadeh, B. M., Taimeh, Z., Alkhatib, L., Alshwayat, A. R. I., Saadeh, N. A., & Al‐kurdi, M. A. (2025) · Future Science OA · doi:10.1080/20565623.2025.2483607 · Cited by 13
The protective role of GLP-1 in neuro-ophthalmology
Sheth, S., Patel, A., Foreman, M. A., Mumtaz, M., Reddy, A., Sharaf, R., Sheth, S., & Lucke-Wold, B. P. (2023) · Exploration of Drug Science · doi:10.37349/eds.2023.00015 · Cited by 12
Makunts, T., Joulfayan, H., & Abagyan, R. A. (2024) · JMIRx Med · doi:10.2196/55976 · Cited by 15
Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
He, X., Zhao, W., Li, P., Zhang, Y., Li, G., Su, H., Lu, B., & Pang, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1483792 · Cited by 17
Buchanan, L., Calkins, M. W., Kalayjian, T., Norwitz, N. G., Teicholz, N., Unwin, D., & Soto-Mota, A. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1548609 · Cited by 12
Semaglutide - properties, action and chromatographic analysis
Wasilewska, B., & Petruczynik, A. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01711-8 · Cited by 11
Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use
Vilsbøll, T., Stellfeld, M., Aroda, V. R., Dandanell, S., David, J., Kristiansen, C. T. P., Rasmussen, S., Roberts, F. L., & Hegedűs, L. D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70291 · Cited by 11
Gu, S. (2026) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s556918 · Cited by 13
Glucagon-like peptide-1 medicines and cancer
Yabut, J. M., & Drucker, D. J. (2026) · Nature Cancer · doi:10.1038/s43018-025-01110-1 · Cited by 13
Alqifari, S. F., Komi, O. A., Esmail, A., Alkhawami, K., Yousri, S., Muqresh, M. A., Alharbi, N., Khojah, A. A. A., Aljabri, A. M., Allahham, A., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.331 · Cited by 11
Paz‐Ibarra, J., Concepción‐Zavaleta, M. J., & Aldave, J. E. Q. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2377687 · Cited by 11
Data mining study on adverse events of tirzepatide based on FAERS database
Huo, Y., Ma, M., & Liao, X. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2376686 · Cited by 11
Grandhi, N., Liu, L., Wang, M., Thomas, T. S., Schoen, M. W., Sanfilippo, K. M., Gao, F., Colditz, G. A., Carson, K. R., Janakiram, M., et al. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae095 · Cited by 12
Stumpf, M. A. M., Cercato, C., de Melo, M. E., Santos, R. D., & Mancini, M. C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad280 · Cited by 12
Update on Pediatric Anti-obesity Medications—Current Landscape and Approach to Prescribing
Ahn, Y. J., Maya, J., & Singhal, V. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00566-z · Cited by 11
Wawrzak-Pienkowska, K., Pienkowski, T., Golonko, A., Krupa, A., Warpechowski, M., Płoński, A. F., Mojsak, P., Daniluk, J., Dâbrowski, A., & Kurek, K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178290 · Cited by 10
Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?
Kaplan, J. M., Zaman, A., & Abushamat, L. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02097-4 · Cited by 11
Glucagon-like peptide-1 receptor agonists in neoplastic diseases
Ji, L., He, X., Min, X., Yang, H., Wu, W., Xu, H., Chen, J., & Mei, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1465881 · Cited by 12
Duchemin, L., Morice, A., Morice, P., Bernardeau, C., Alexandre, J., Fédrizzi, S., Silva, A. D., Boismoreau, L., Faillie, J., & Dolladille, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16504 · Cited by 13
Self-citationAdipose Tissues Have Been Overlooked as Players in Prostate Cancer Progression
Liermann-Wooldrik, K. T., Kosmacek, E. A., & Oberley‐Deegan, R. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212137 · Cited by 11
Gallucci, G., Larocca, M., Navazio, A., Turazza, F. M., Inno, A., Canale, M. L., Oliva, S., Besutti, G., Tedeschi, A., Aschieri, D., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010334 · Cited by 9
Ruggiero, R., Longo, M., Mascolo, A., Nuzzo, M. D., Laino, L. V., Caruso, P., D'Amato, R., Rafaniello, C., Maiorino, M. I., Esposito, K., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178004 · Cited by 9
Stachteas, P., Nasoufidou, A., Karakasis, P., Koiliari, M., Karagiannidis, E., Koufakis, T., Fragakis, N., & Patoulias, D. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39691 · Cited by 11
Tang, Z., Xu, N., Lyu, P., Zhao, H., & Zheng, W. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101420 · Cited by 10
GLP-1 signaling in tumor metabolism and immunity: mechanisms and strategies
Luo, Y., Xu, H., Zhao, Y., Yang, B., & Zhang, Y. (2025) · Food & Function · doi:10.1039/d5fo03273c · Cited by 9
Glucagon-Like Peptide-1 Receptor Agonists and Chronic Cough
Gallagher, T. J., Razura, D. E., Li, A., Kim, I., Vukkadala, N., & Barbu, A. M. (2025) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2025.4181 · Cited by 9
Goldenberg, R., & Jain, A. (2023) · Diabetes Care · doi:10.2337/dc22-2300 · Cited by 9
McIntyre, R. S. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20241087 · Cited by 10
Current and emerging medications for the management of obesity in adults
Walmsley, R., & Sumithran, P. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.52031 · Cited by 8
Timosaponin A3 Induces Anti-Obesity and Anti-Diabetic Effects In Vitro and In Vivo
Park, J.-H., Jee, W., Park, S.-M., Park, Y.-R., Kim, S. W., Bae, H., Chung, W., Cho, J., Kim, H., Song, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052914 · Cited by 8
Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks
Thota-Kammili, S., Tama, E., & Andrade, M. D. H. (2024) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00452-6 · Cited by 9
Practical application of semaglutide: From evidence-based research to expert decisions
Салухов, В. В., Galstyan, G. R., Khalimov, Y. S., Бакулин, И. Г., Cherkashin, D. V., Shadrichev, F. E., & Sukhotskaia, N. A. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-185 · Cited by 8
Obesity and Metabolic Syndrome: Current Insights and Future Directions
Zarkasi, Z., Mudaliar, R. N., Majeed, W., & Syed, A. A. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2025.0127 · Cited by 10
Kowalska, M. K., El‐Mallul, A., Hudecka, W., Lubojańska, J. E., Lubojański, P. J., Orłowska, S. M., & Bednarczyk, Ł. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041886 · Cited by 9
The effect of antidiabetic drugs on bone metabolism: a concise review
Psachna, S., Chondrogianni, M. E., Stathopoulos, K. D., Polymeris, A., Chatzigeorgiou, A., Chronopoulos, E., Tournis, S., & Kassi, E. N. (2024) · Endocrine · doi:10.1007/s12020-024-04070-1 · Cited by 8
A novel risk factor for malignancy: Albuminuria
Kanbay, M., Çöpür, S., Yilmaz, Z. Y., Tanrıöver, C., Hasbal, N. B., Ortíz, A., & Perazella, M. A. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.09.010 · Cited by 8
Chee, Y. J., & Dalan, R. (2024) · Biomedicines · doi:10.3390/biomedicines12071386 · Cited by 7
Bezin, J., Mathieu, C., Faillie, J.-L., & Pariente, A. (2023) · Diabetes Care · doi:10.2337/dci23-0016 · Cited by 7
Self-citationCardiovascular effects of anti-obesity medications: the perils and promise
Zheng, H. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000114 · Cited by 7
Evaluating Thyroid Cancer Risk in Glucagon-like Peptide-1 Analog Users With Thyroid Nodules
Balachandra, S., Syed, R., Song, Z., Kasmirski, J. A., Gillis, A., Fazendin, J. M., Lindeman, B. M., & Chen, H. (2025) · Journal of Surgical Research · doi:10.1016/j.jss.2025.05.016 · Cited by 7
Pharmacologic Therapies for Type 2 Diabetes
Kuo, B., & Li, J. H. (2025) · NEJM Evidence · doi:10.1056/evidra2400265 · Cited by 8
He, X., Zhao, Z., Sun, Y., & Jiang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118163 · Cited by 8
Cancer related safety with SGLT2-i and GLP1-RAs: Should we worry?
Gallo, M., Monami, M., Ragni, A., & Renzelli, V. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110624 · Cited by 7
Cheng, Z., Wang, S., Li, F., Jin, C., Mo, C., Zheng, J., Li, X., Liang, F., Yang, J.-K., & Gu, D. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.70013 · Cited by 9
Smits, M. M., & van Raalte, D. H. (2023) · Diabetes Care · doi:10.2337/dc23-0134 · Cited by 7
Humaida, S., Manzalji, K., Seyam, N. I., & Masalmani, L. A. (2025) · Cureus · doi:10.7759/cureus.85123 · Cited by 6
Ipaye, T., Goldney, J., Wilkinson, T. J., Zaccardi, F., Yates, T. E., Davies, M. J., Brown, K., & Papamargaritis, D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70090 · Cited by 8
Ismail, A., Amer, M. S., & Tawheed, A. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i3.107148 · Cited by 6
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 12
Metoyer, G. T., Whiteson, H. Z., Chen, Y., Li, Y., Gao, C., Menon, G., Bae, S., Lentine, K. L., Segev, D. L., McAdams‐DeMarco, M., et al. (2025) · Clinical Transplantation · doi:10.1111/ctr.70354 · Cited by 7
Current and Future Pharmacological Interventions for Acquired Hypothalamic Obesity
Roth, C. L., Doelman-Oldenburger, N. J., & van Santen, H. M. (2026) · Drugs · doi:10.1007/s40265-025-02280-z · Cited by 7
Blockbuster Medications for Obesity: A Primer for Nephrologists
Zeitler, E. M., Dabb, K., Nadeem, D., Still, C. D., & Chang, A. R. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.04.009 · Cited by 6
Elfers, C., Chichura, K. S., Ashlaw, E. F., Chepurny, O. G., Holz, G. G., Doyle, R. P., & Roth, C. L. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.05.035 · Cited by 7
Use of GLP-1 Receptor Agonists for the Management of Type 1 Diabetes: A Pediatric Perspective
Nevo-Shenker, M., & Shalitin, S. (2024) · Hormone Research in Paediatrics · doi:10.1159/000541228 · Cited by 7
Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
Sundararaman, L. V., Gouda, D., Kumar, A., Sundararaman, S., & Goudra, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061978 · Cited by 7
Elangovan, H., Gunton, J. E., Zheng, M., Fan, J.-G., Goh, G. B., Grønbæk, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10795-6 · Cited by 7
Salama, L., & Sinn, L. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf053 · Cited by 8
Gautier, P., Elbaz, M., Bouisset, F., Despas, F., & Montastruc, F. (2025) · Drug Safety · doi:10.1007/s40264-025-01546-5 · Cited by 6
Wu, R., Zhang, J., Zou, G., Li, S., Wang, J., Li, X., & Xu, J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s450321 · Cited by 6
Cancer biology in diabetes update: Focusing on antidiabetic drugs
Kawakita, E., & Kanasaki, K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14152 · Cited by 8
Endo, M., Roth, M. Y., Tylee, T. S., DeSantis, A., & Hirsch, I. B. (2023) · Diabetes Care · doi:10.2337/dc22-2454 · Cited by 6
Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation
Alansari, A., Alharbi, A. S., Alshehri, K., Alhabib, A. T., Alsalmi, B. S., Almosfer, W. A., AlAjlan, F. A., Alharbi, A., Alzahrani, B. S., Alamer, B. A. N., et al. (2025) · Medicine · doi:10.1097/md.0000000000046173 · Cited by 5
The male hormone reset: how GLP-1RAs, lifestyle and testosterone transform obesity-linked problems
Antonič, K. G., & Zitzmann, M. (2025) · The Aging Male · doi:10.1080/13685538.2025.2601423 · Cited by 6
Xu, J., Wang, S., Wu, H., Chen, D., Han, J. D. J., & Lin, Q. (2023) · Peptides · doi:10.1016/j.peptides.2023.171073 · Cited by 5
A System-Based Review on Effects of Glucagon-Like Peptide-1 Receptor Agonists: Benefits vs Risks
Fadel, L. P., Thao, G., Chitre, T., Rojas, E. D., Fricko, M. N., Domingo, V., Budginas, B., Guerrero, L. C., Ghatas, M., Arani, N. T., et al. (2025) · Cureus · doi:10.7759/cureus.78575 · Cited by 5
Titus, J., Katukuri, V. K., Boktor, M., & Mansi, I. A. (2025) · Drug Safety · doi:10.1007/s40264-025-01558-1 · Cited by 5
Mañas-Martinez, A. B., & Gimeno-Orna, J. A. (2023) · Diabetes Care · doi:10.2337/dc23-0076 · Cited by 5
GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Pourkarim, F., & Entezari‐Maleki, T. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2311840 · Cited by 5
Beheshtirouy, S., & Shayanfar, A. (2024) · JAMA · doi:10.1001/jama.2024.5998 · Cited by 5
Effect of GLP-1 Receptor Agonists on Patients with Thyroid Carcinomas Undergoing Active Surveillance
Patrizio, A., Newman, S. K., Tuttle, R. M., & Boucai, L. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf182 · Cited by 5
Eze, E. D., Ntakirutimana, L., Terkimbi, S. D., Walle, M., Umar, A. H., Wondimu, D. H., Olubiyi, M. V., Okeke, O. C., Onaadepo, O., Abdulazeez, J., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1859759 · Cited by 4
Ruggeri, R. M., Grossrubatscher, E. M., Ciocca, E., Hasballa, I., Jaafar, S., Oldani, M., Rubino, M., Russo, F., Isidori, A. M., Colao, A. A. L., et al. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09958-5 · Cited by 5
Barrea, L., Caprio, M., Perrini, S., Camajani, E., Crafa, A., Gangitano, E., Gorini, S., Sciacca, L., Verde, L., Albertelli, M., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02589-2 · Cited by 5
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16434 · Cited by 6
Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer
Patrizio, A., Mauguen, A., Fagin, J. A., Farooki, A., Fish, S. A., Flory, J., Newman, S. K., Presswala, L. S., Sabra, M. M., Tuttle, R. M., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag051 · Cited by 4
Obesity, type 2 diabetes and cancers of the digestive system
Cernea, S., Crișan, D., Lăcătușu, C.-M., Zaharia, O., & Gancheva, S. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.02.003 · Cited by 5
Thyroid Cancer Risk with GLP-1 Receptor Agonists: Evidence, Knowledge Gaps, and the Path Forward
Toro-Tobón, D., Ospina, N. S., & Brito, J. P. (2025) · Thyroid · doi:10.1089/thy.2024.0690 · Cited by 4
Weight-centric prevention of cancer
Añazco, D., Acosta, A. J., Cathcart-Rake, E. J., D’Andre, S. D., & Hurtado, M. D. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100106 · Cited by 5
Treatments for weight gain in schizophrenia
Elman, I. (2025) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000992 · Cited by 3
The Cardiovascular Benefits of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Kallash, M., & Frishman, W. H. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000970 · Cited by 3
Dayel, F. F. B., Alanazi, R. J., Alenazi, M. A., Alkhalifah, S., Alfaifi, M., Alghadeer, S. M., & Alwhaibi, A. M. (2025) · Healthcare · doi:10.3390/healthcare13151827 · Cited by 3
Can GLP-1RAs redefine transplantation standard of care?
Almalki, B. A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.08.013 · Cited by 4
Acheampong, C. O., Buse, J. B., Klein, K. R., Kim, L. T., Evron, J. M., Kahkoska, A. R., Thompson, C. A., Wang, T., Pate, V., Leese, P., et al. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005090 · Cited by 3
Hindi, A. M. K., Mekkawy, M. A., & Shokr, H. (2026) · Pharmaceuticals · doi:10.3390/ph19030365 · Cited by 5
Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden
Dugbartey, G. J., Alornyo, K. K., Dapaa-Addo, C. O., Kwashie, E. K., Harley, Y., & Asiedu, B. N. (2026) · Toxicology Reports · doi:10.1016/j.toxrep.2026.102247 · Cited by 5
Current options in obesity pharmacotherapy for children and adolescents
Jung, H. W. (2024) · Precision and Future Medicine · doi:10.23838/pfm.2024.00093 · Cited by 3
Romeo, M., Nardo, F. D., Napolitano, C., Basile, C., Palma, C., Vaia, P., Dallio, M., & Federico, A. (2025) · Diabetology · doi:10.3390/diabetology6080079 · Cited by 3
Hurwitz, S. R., Lanes, S., Quimbo, T., Papazian, A., White, J., Fisher, V. L., Cziraky, M. J., Crowley, M. J., & Willey, V. J. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70214 · Cited by 6
Effect of glucagon-like peptide-1 receptor agonists on prostate cancer: A review
Xu, Y., & Liu, J. (2024) · Medicine · doi:10.1097/md.0000000000039956 · Cited by 3
Vambe, S., Zulu, W., Hough, E., Luvhimbi, M., Rwizi, S., & Bronkhorst, E. M. (2024) · SA pharmaceutical journal. · doi:10.36303/sapj.1143 · Cited by 3
Dong, J., Starkey, T., Cheng, V. W. T., Clark, J., Pinato, D. J., Robinson, T., Tilby, M., Turnbull, C. D., & Lee, L. Y. W. (2025) · Cancer Epidemiology · doi:10.1016/j.canep.2025.102837 · Cited by 4
Sauter, E. R., & Agurs‐Collins, T. (2024) · Cancers · doi:10.3390/cancers16193275 · Cited by 2
Opalska, L., Muciek, A., Mocarska, M., Orłowska, A., Strakowska, K., Maryńczak, A., Mencel, J., & Nitschke, N. (2024) · Quality in Sport · doi:10.12775/qs.2024.35.56425 · Cited by 2
Hollingshead, B. D., & Radi, Z. A. (2025) · Journal of Applied Toxicology · doi:10.1002/jat.4779 · Cited by 3
A Perfect MASH Comparing Resmetirom and GLP-1 Agonists for Metabolic-Associated Steatohepatitis
Lin, J., Green, V., Sohal, A., & Roytman, M. M. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002234 · Cited by 3
Seidel, D. U., & Bode, S. (2025) · HNO · doi:10.1007/s00106-025-01653-w · Cited by 2
Lingow, S. E., Carris, N. W., Clements, J. N., Courtney, L. A., Lennon, A., Sherrill, C. H., & Dril, E. V. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70111 · Cited by 5
Ziyanok, S. (2025) · Doğu Karadeniz Sağlık Bilimleri Dergisi · doi:10.59312/ebshealth.1765591 · Cited by 2
Anti-diabetic medications and cancer: links beyond glycemic and body weight control
Cao, M., Lin, C., Cai, X., Lv, F., Yang, W., & Ji, L. (2025) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaf028 · Cited by 2
Metadata
- Authors
- Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L.
- Affiliations
- Université de Bordeaux (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- 4Département de Pharmacologie Médicale et Toxicologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
- Inserm (FR)
- Corresponding author
- Faillie, Jean-Luc
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-11-10
- Volume
- 46
- Issue
- 2
- Pages
- 384-390
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4308701204
- Cited by
- 320
- References
- 17
- Citations by year
- 2026: 64 · 2025: 118 · 2024: 94 · 2023: 42 · 2022: 2
- FWCI
- 47.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
- Funders
- Agence Nationale de Sécurité du Médicament et des Produits de Santé (2019S015)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- GLP-1 receptor agonists, thyroid cancer, medullary thyroid carcinoma, type 2 diabetes, drug safety, cancer risk, treatment duration
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Thyroid Neoplasms, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
